Hims & Hers Health, Inc. SEC Filings

Form 144 filed for Hims & Hers Health, Inc. (HIMS) reporting a proposed sale of Class A common stock. The notice identifies a proposed sale of 175,661 Class A shares through Fidelity Brokerage Services LLC with an aggregate market value of $9,384,625.88 and lists 217,641,958 shares outstanding. The filing shows acquisition dates for the shares to be sold: restricted stock vesting on 03/15/2022, 03/15/2023, 06/15/2023, and 06/15/2024 (totaling listed smaller lots), and an option grant payable in cash on 09/16/2025 for 125,335 shares. The approximate date of sale is 09/16/2025 on the NYSE. The filing also discloses multiple sales by the seller(s) during the past three months with amounts and gross proceeds for each transaction. The form includes the required signature representation about material nonpublic information.

Form 144 filed for Hims & Hers Health, Inc. (HIMS) discloses a proposed sale of 145,000 shares of common stock through Goldman Sachs & Co. LLC on 09/15/2025 with an indicated aggregate market value of $7,824,200. The filing lists the securities to be sold as consisting of previously granted compensation instruments, including multiple restricted stock unit grants dated 06/15/2024, 09/15/2024 and several stock option cashless exercises dated 02/24/2022 through 08/24/2025. The filer also reported a series of sales by Oluyemi Okupe in June–August 2025 (examples: 23,107 shares on 06/23/2025; 11,581 shares on 07/07/2025 and additional July/August trades) with reported gross proceeds for each transaction. The notice includes the required signature representation regarding material nonpublic information.

Form 144 notice by a holder of HIMS Class A shares reports a proposed sale and recent sales activity. The filer intends to sell 4,150 Class A shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $232,400 and an approximate sale date of 09/15/2025. The securities to be sold were acquired on 09/15/2025 by exercise of options granted on 08/10/2022, 02/24/2022 and 03/01/2023 (1,800; 2,100; and 250 shares respectively) with cash payment. The notice lists five Class A sales by Michael Y. Chi between 06/17/2025 and 08/01/2025 totaling 83,552 shares for gross proceeds of approximately $3,693,196.50. The signer represents no undisclosed material adverse information.

Hims & Hers Health, Inc. disclosed a lease and related guaranty executed on September 1, 2025. The lease has an initial 15-year term with two successive five-year extension options and a Rent Commencement Date of April 1, 2026. The first-year annual base rent is $5,984,204 (about $498,684 per month) and will escalate ~3.25% annually. Base rent is fully abated from the Lease Commencement Date through the day before the Rent Commencement Date, and a monthly abatement of $262,838.42 applies for five months after rent begins. Hims is responsible for operating expenses starting at Rent Commencement. A $5,984,204 letter of credit from JPMorgan Chase secures Hims’ obligations, and the company filed a guaranty of the lease.

Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options for 11,581 shares of Class A Common Stock at $5.0100 per share on August 26, 2025, then sold 11,581 shares at a weighted-average price of $43.6895 pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024. After these transactions, he holds 116,806 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust.

Insider sale by HIMS officer: The Form 4 shows Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 2,571 shares of Class A common stock on 08/25/2025 at a price of $44.53 per share. After the reported sale, Boughton beneficially owned 150,450 shares. The filing was signed by an attorney-in-fact on 08/26/2025 and indicates the sale was executed under the reporting person’s authority.

Form 144 filed relating to HIMS (HIMS): The notice reports a proposed sale of 2,571 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $114,486.63 and an approximate sale date of 08/25/2025. The shares were acquired on 06/15/2025 by Restricted Stock Vesting from the issuer and were paid as compensation. The filing lists multiple prior Class A sales by Soleil Boughton between 05/27/2025 and 08/11/2025, showing amounts and gross proceeds for each trade. Some issuer and filer identifying fields in the header are blank or not provided in the document.

Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on 08/18/2025 conducted under a Rule 10b5-1 plan. The filing shows option exercises at an exercise price of $2.43 for 17,001 and 108,334 options, and subsequent sales of shares from those exercises and existing holdings at average weighted prices in the mid-$44 to mid-$45 range. Reported sales on that date include blocks of 47,534; 2,792; 17,001; 41,667; 50,000; and 16,667 shares at various average prices around $44.76–$45.42. Post-transaction beneficial ownership across direct and indirect holdings is reported for numerous trusts, with notable indirect positions such as 1,016,871 and 2,214,769 shares held by trustees. The Form 4 is signed by an attorney-in-fact on 08/20/2025.

Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports proposed and recent sales of Class A common stock by insiders and related parties. The filing lists a proposed sale of 47,534 shares via Fidelity (approximate market value $2,141,494) with an approximate sale date of 08/18/2025 on the NYSE. It shows acquisition details for 46,534 vested restricted shares received in 2022 and 2023 as compensation. The filing also discloses multiple completed insider sales between 06/16/2025 and 07/21/2025 totaling several hundred thousand shares and gross proceeds in the multi‑million dollar range. The filer certifies they are not aware of undisclosed material adverse information.